Post Traumatic Stress Disorder Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight

DelveInsight’s Post Traumatic Stress Disorder Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LA, UNITED STATES, June 25, 2024 /EINPresswire.com/ --
DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Post Traumatic Stress Disorder, historical and forecasted epidemiology as well as the Post Traumatic Stress Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Post Traumatic Stress Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post Traumatic Stress Disorder Market Forecast

Some of the key facts of the Post Traumatic Stress Disorder Market Report:
The Post Traumatic Stress Disorder market size was valued ~USD 1,760 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In November 2023, Silo Pharma has secured an exclusive license agreement with Medspray Pharma BV for intranasal technology utilized in the SPC-15 treatment targeting PTSD.
In September 2023, The US FDA reported favorable initial findings from its Phase IIb ATTUNE trial evaluating BNC210 for PTSD treatment.
In 2023, there were approximately 13.8 million prevalent cases of PTSD across the 7MM. These numbers are projected to rise in the forecasted period. The highest prevalence of PTSD cases was noted in the United States.
In the EU4 countries and the UK, there were approximately 3.387 million prevalent cases of PTSD in 2023, with expectations for an increase in the forecasted period.
In 2023, there were around 4.201 million cases of PTSD among males and approximately 9.6 million cases among females across the 7MM.
In 2023, PTSD cases were categorized by severity as approximately 4.43 million cases for mild, around 4.36 million cases for moderate, and about 5 million cases for severe across the 7MM.
In 2023, the total number of treated PTSD cases was approximately 2.5 million across the 7MM, with expectations for an increase during the forecast period.
Key Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others
Key Post Traumatic Stress Disorder Therapies: REXULTI ± ZOLOFT, NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others
The Post Traumatic Stress Disorder epidemiology based on gender analyzed that females are more affected with PTSD than females
The Post Traumatic Stress Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post Traumatic Stress Disorder pipeline products will significantly revolutionize the Post Traumatic Stress Disorder market dynamics.

Post Traumatic Stress Disorder Overview
A person who has experienced or witnessed a traumatic event, such as a natural disaster, a serious accident, a terrorist act, war or combat, or rape, or who has been threatened with death, sexual assault, or serious injury, may develop post-traumatic stress disorder (PTSD), a chronic psychiatric disorder.

Get a Free sample for the Post Traumatic Stress Disorder Market Report -
https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Post Traumatic Stress Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post Traumatic Stress Disorder Epidemiology Segmentation:
The Post Traumatic Stress Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Post Traumatic Stress Disorder
Prevalent Cases of Post Traumatic Stress Disorder by severity
Gender-specific Prevalence of Post Traumatic Stress Disorder
Diagnosed Cases of Episodic and Chronic Post Traumatic Stress Disorder

Download the report to understand which factors are driving Post Traumatic Stress Disorder epidemiology trends @ Post Traumatic Stress Disorder Epidemiology Forecast

Post Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post Traumatic Stress Disorder market or expected to get launched during the study period. The analysis covers Post Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Post Traumatic Stress Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post Traumatic Stress Disorder Therapies and Key Companies
REXULTI ± ZOLOFT: Otsuka Pharmaceutical
NBTX001: Nobilis Therapeutics
Brexpiprazole: Otsuka Pharma
COMP360: Compass Pathways
NYX-783: Aptinyx
JZP150: Jazz Pharmaceuticals
Psilocybin: COMPASS Pathways
BNC210: Bionomics Limited
BI 1358894: Boehringer Ingelheim
orvepitant: GlaxoSmithKline
Psilocybin: KGK Science Inc.
Quetiapine Fumarate: AstraZeneca
levetiracetam: UCB Pharma
BX-1: Bionorica SE
Ziprasidone: Pfizer

Post Traumatic Stress Disorder Market Strengths
New diagnostic categories modeled on PTSD have been proposed, including prolonged duress stress disorder, post-traumatic grief disorder, post-traumatic relationship syndrome, post-traumatic dental care anxiety, and post-traumatic abortion syndrome.

Post Traumatic Stress Disorder Market Opportunities
The introduction of novel drugs and the class of new therapeutic drugs to treat PTSD in the market will bring hope to the PTSD patients as a therapeutic option and might have a major positive effect on the market.

Scope of the Post Traumatic Stress Disorder Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others
Key Post Traumatic Stress Disorder Therapies: REXULTI ± ZOLOFT, NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others
Post Traumatic Stress Disorder Therapeutic Assessment: Post Traumatic Stress Disorder current marketed and Post Traumatic Stress Disorder emerging therapies
Post Traumatic Stress Disorder Market Dynamics: Post Traumatic Stress Disorder market drivers and Post Traumatic Stress Disorder market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Post Traumatic Stress Disorder Unmet Needs, KOL’s views, Analyst’s views, Post Traumatic Stress Disorder Market Access and Reimbursement

To know more about Post Traumatic Stress Disorder companies working in the treatment market, visit @ Post Traumatic Stress Disorder Clinical Trials and Therapeutic Assessment

Table of Contents
1. Post Traumatic Stress Disorder Market Report Introduction
2. Executive Summary for Post Traumatic Stress Disorder
3. SWOT analysis of Post Traumatic Stress Disorder
4. Post Traumatic Stress Disorder Patient Share (%) Overview at a Glance
5. Post Traumatic Stress Disorder Market Overview at a Glance
6. Post Traumatic Stress Disorder Disease Background and Overview
7. Post Traumatic Stress Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Post Traumatic Stress Disorder
9. Post Traumatic Stress Disorder Current Treatment and Medical Practices
10. Post Traumatic Stress Disorder Unmet Needs
11. Post Traumatic Stress Disorder Emerging Therapies
12. Post Traumatic Stress Disorder Market Outlook
13. Country-Wise Post Traumatic Stress Disorder Market Analysis (2020–2034)
14. Post Traumatic Stress Disorder Market Access and Reimbursement of Therapies
15. Post Traumatic Stress Disorder Market Drivers
16. Post Traumatic Stress Disorder Market Barriers
17. Post Traumatic Stress Disorder Appendix
18. Post Traumatic Stress Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here